Fairvalue-Calculator Fairvalue-Calculator
EN DE

Agios Pharmaceuticals, Inc (AGIO) Fair Value & Analysis

Healthcare · US · Market cap $2.0B

Price$36.28
Fair Value$10.35
Upside-71.5%
Quality95/100
Evidence: Low Range $5.34 – $15.23

Fair value as of: Jun 25, 2026

Analysis

Agios Pharmaceuticals, Inc (AGIO) currently trades at $36.28, while our model-based Fair Value estimate is $10.35 — implying the stock looks roughly 71.5% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatme…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Agios Pharmaceuticals, Inc (AGIO) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $10.35 versus a price of $36.28 — about −71% (overvalued). Model-based estimate, not financial advice.
What is the fair value of AGIO?
Our 21-model fair value for Agios Pharmaceuticals, Inc is $10.35 (as of Jun 25, 2026), built from audited fundamentals. The current price is $36.28.
What is the quality score of AGIO?
Agios Pharmaceuticals, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.